Background Although the live attenuated influenza vaccine (LAIV) prescribing information contains warnings ⁄ precautions against use during pregnancy, administration of LAIV to pregnant women does occur. Data regarding maternal outcomes after LAIV administration during pregnancy are limited.
Introduction
Women who are pregnant during the influenza season are at increased risk for severe complications from influenza infections. [1] [2] [3] For this reason, influenza vaccination at any time during pregnancy is recommended by the US Advisory Committee on Immunization Practices (ACIP) and the American College of Obstetricians and Gynecologists (ACOG). 1, 4 Two types of influenza vaccines are approved in the United States: injectable trivalent inactivated influenza vaccines (TIV) and the intranasal live attenuated influenza vaccine (LAIV). The safety of TIV during pregnancy has been well established. 5, 6 Accordingly, the US Centers for Disease Control and Prevention (CDC) recommend that TIV are used to vaccinate pregnant women during the influenza season. As with all live vaccines, LAIV is not recommended for use during pregnancy. 1, 7 LAIV is approved in the United States for use in eligible children and adults 2-49 years of age, and more than 40 million doses of seasonal trivalent LAIV have been distributed for use in the United States from licensure in 2003 through the 2010-2011 influenza season (MedImmune, data on file).
It is not known whether LAIV administration during pregnancy is associated with any maternal or fetal risks. To date, there has been little information available. A 2010 analysis of data from the Vaccine Adverse Events Reporting System (VAERS) reported 27 pregnant women from 2003 through 2009 who received LAIV, 60% of whom did not report any associated adverse event. 8 Of those reporting adverse events, the most common were spontaneous abortion (n = 3), fever (n = 3), vomiting (n = 3), headache Original Article (n = 3), and sore throat (n = 2). No congenital anomalies or adverse fetal events were reported. Additionally, a study by Piedra et al. 9 described fetal outcomes among six adolescents who were inadvertently vaccinated with LAIV while pregnant. Among these pregnancies, there were five fullterm healthy infants and one preterm delivery. The lack of available information regarding maternal and fetal risks after LAIV vaccination and concerns regarding inadvertent vaccination of pregnant women has complicated vaccination efforts in some settings. 10 Although LAIV is not recommended to be administered to pregnant women, administration of LAIV to pregnant women does rarely occur. The purpose of this study was to quantify, using healthcare claims data, the frequency of LAIV vaccination among pregnant women and to assess maternal adverse events after vaccination with LAIV.
Methods
Anonymized patient-specific claims data were obtained from the LifeLinkÔ Health Plan Claims Database (IMS Health, Norwalk, CT, USA). At the time of data acquisition, the database included medical and pharmacy claims from more than 50 million unique members from over 90 U.S. health plans. The database includes inpatient and outpatient claims, including diagnoses in ICD-9-CM format, procedures in CPT-4 and HCPCS formats, and retail and mail-order pharmacy claims containing National Drug Codes (NDC). Date and place of service are included with all claims. Information regarding influenza vaccinations for which claims were not submitted was unavailable.
The study population consisted of females who were 12-49 years of age at the time they had a claim for delivery of a child. For inclusion, individuals were required to have at least 270 days of continuous enrollment in the database before delivery. Data from October 2003 through September 2009 were included in the analysis. Because the database was unable to link claims data for a mother and her offspring, no fetal outcomes could be examined.
Pregnant women were identified by a claim for a delivery procedure code or an ICD-9-CM diagnosis code for a delivery. Women could contribute more than one pregnancy and delivery to the analysis as long as the aforementioned criteria were met for each included delivery. For pregnancies with multiple delivery codes during the period of pregnancy, the investigators manually reviewed the claims to ascertain the correct delivery date based on the date of the delivery procedure code; if no delivery procedure code was present, the delivery date was assigned to be the date of the first ICD-9-CM diagnosis code for a delivery. LAIV exposure during pregnancy was identified by the presence of CPT code 90660 or an NDC code of 66019010001, 66019020001, 66019030001, 66019040001, 66019050001, or 66019060001. TIV exposure was defined by the presence of an insurance claim with a CPT code of 90655, 90656, 90657, 90658, 90659, or relevant NDC code. The 2009 monovalent H1N1 pandemic influenza vaccines were not in use at the time of the study and were not included in the analysis.
For each pregnancy, a date of conception was calculated by estimating the duration of pregnancy from ICD-9-CM codes associated with the delivery. If an ICD-9-CM code for gestational age (765AE2x) was recorded at the time of delivery, the conception date was assumed to precede delivery by the upper limit of the range of weeks associated with the specific code. We used the upper limit to maximize the detection of LAIV vaccination during pregnancy. If the 765AE2x codes were not present, but premature delivery was indicated by codes 644AE20 or 644AE21, the date of conception was assumed to be 245 days before delivery, the approximate gestational age for children born <37 weeks as described by Martin et al. 11 If neither the 765AE2x nor the 644AE2x codes were present, but the birth involved multiple infants, then the conception date was assumed to be 256 days before delivery, the midpoint of the range of days used by Cole et al. 12 For all other pregnancies, the conception date was estimated as the date 270 days before delivery. 13 The end of the first and second trimesters was defined as 90 and 180 days after conception, respectively; the end of the third trimester was the delivery date. The gestational day at the time of vaccination was defined as the number of days between LAIV vaccination and the estimated date of conception.
To evaluate the presence of underlying high-risk medical conditions, available ICD-9-CM codes from claims as early as January 1997 to the time of vaccination were reviewed. To qualify as having a high-risk condition, a subject had to have at least one hospital ⁄ emergency department (ED) claim or two outpatient claims on separate dates for the condition on or before the delivery date. The following ICD-9-CM codes were used to define high-risk disease groups: chronic cardiac disease ( To assess potential adverse outcomes among the cohort of women vaccinated with LAIV during pregnancy, all health insurance claims for hospitalization or ED visits occurring within 42 days post-vaccination were reviewed. Because the sample of LAIV-vaccinated pregnant women was small, a qualitative description of adverse outcomes in comparison with the rates published in the medical literature was provided. For each hospitalization or ED visit, authors reviewed the primary discharge diagnoses and grouped events into three categories: obstetric outcomes (those not related to delivery), cardiopulmonary outcomes, and other medical outcomes. For hospitalizations within 42 days post-vaccination listing a primary discharge diagnosis of normal delivery, all additional codes associated with that hospitalization were also reviewed. Any diagnosis code for a previously unrecorded medical condition that was not related to routine labor and delivery and not related to a fetal condition was considered to be a potential outcome of interest. To evaluate any potential long-term side effects of vaccination, primary discharge diagnoses associated with hospitalizations from the time of vaccination up until, but not including, the hospitalization at the time of delivery were analyzed. To focus on serious adverse events, only hospitalizations were considered in this analysis. If a subject had a claim for an ED visit and hospitalization on the same day, a single hospitalization event was counted. The number and percentage of women who experienced either a hospitalization or ED visit was stratified by trimester of vaccination. Women with high-risk medical conditions were included in the analysis and examined separately.
Because the delivery of a child was an entry criterion and delivery data were only available through September 2009, the 2008-2009 cohort would not include first-trimester vaccinations of women with deliveries after September 2009. All analyses were performed using SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA) or Microsoft Excel (Microsoft, Redmond, WA, USA). Because data were anonymized, the protocol was granted Institutional Review Board (IRB) review exemption by the RTI International IRB. (Table 1) , with the exception of LAIV-vaccinated women having a greater likelihood of being £19 years of age (13% versus 5%; P < 0AE0001) and of having >10 prenatal visits (21% versus 13%; P < 0AE01). LAIV-vaccinated women were also less likely to have a claim for vaccination with TIV (4% versus Table 1 . Characteristics of LAIV-vaccinated and LAIV-unvaccinated cohorts Significantly different than LAIV non-exposed, P < 0AE01.
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; P < 0AE01). Of those vaccinated with LAIV, 47%, 27%, and 26% were vaccinated in the first, second, and third trimesters, respectively. Among the 65 first-trimester exposures, 42 occurred during the first 6 weeks of pregnancy. When trimester of vaccination was analyzed by influenza season, no trends were discernible among the small number of vaccinations occurring each season (Fig. 1) . Women vaccinated in each trimester were comparable with similar mean age, number of high-risk medical conditions, and number of prenatal visits. In addition to pregnancy, 21 women had an underlying high-risk medical condition, specifically cardiac disease, pulmonary disease, diabetes mellitus, or malignancy. Six patients vaccinated with LAIV also had a claim for TIV during pregnancy; in 5 of the 6 patients, the TIV claim occurred on the same date as the LAIV claim. All LAIV vaccinations occurred between September and February of each influenza season, with 87% occurring in October through December. The specialty of the vaccinating physician was only available in 26 of the 138 cases and therefore was not evaluated.
Eight unique individuals were found to have a claim for a hospitalization or ED visit within 42 days post-vaccination with LAIV (three hospitalizations, five ED visits; Table 2 ). Two events were obstetric in nature (hyperemesis gravidarum and threatened premature labor), one event was cardiopulmonary in nature (bronchitis), and five events were because of other medical conditions (pyelonephritis, epigastric symptoms, limb pain, diarrhea, and chest pain). One woman was hospitalized twice for the same diagnosis (threatened premature labor without delivery) on days 9 and 12 post-vaccination, which was counted as a single hospitalization. The three women with ED visits for limb pain, chest pain, and bronchitis, respectively, had pre-existing diagnoses of degenerative thoracic scoliosis, diabetes mellitus, and asthma with congestive heart failure, respectively. Overall, 5AE8% of women experienced a hospitalization or ED visit within 42 days post-vaccination with LAIV; 1AE4%, 0AE7%, and 3AE6% experienced an obstetric event, cardiopulmonary event, and other medical event, respectively. The rates of hospitalization and ⁄ or ED visits within 42 days post-vaccination were higher among women vaccinated in the first and second trimesters (6AE2% and 8AE1%, respectively) than among women vaccinated in the third trimester (2AE8%). Similarly, 14AE3% of women with high-risk underlying conditions experienced an event (three events among 21 women) compared with 4AE3% of women without high-risk conditions (five events among 117 women).
Nineteen women were hospitalized for a delivery within 42 days post-vaccination. Among these women, four maternal medical conditions that had not been previously diagnosed during pregnancy and that were unrelated to routine delivery were noted (polyhydramnios, anemia of pregnancy, premature rupture of membranes, and transient hypertension). Five additional hospitalizations that occurred more than 42 days post-vaccination were noted before delivery (Table 3) . Diagnoses included three obstetric conditions (cervical carcinoma in situ, other placental condition, and breech presentation) and two infections (pyelonephritis and influenza). The subject who was hospitalized for pyelonephritis had a history of recurrent urinary tract infections, before, during, and after pregnancy and was the same subject who was hospitalized for pyelonephritis within 42 days post-vaccination. The subject hospitalized for influenza was vaccinated with LAIV in December 2008 and diagnosed with influenza in August 2009. Both hospitalizations for code 644AE03 occurred in the same subject on separate days. § Same subject hospitalized for diagnosis code 590AE80 on day 6 post-vaccination.
each season. When LAIV use in pregnancy does occur, it is more likely to occur in adolescents, which is not surprising given the extensive use of the vaccine in children and adolescents in the U.S. Additionally, LAIV use in pregnancy is most likely to occur very early in the pregnancy, when a pregnancy may be unrecognized. For second-and third-trimester vaccinations, it is likely that the pregnancy was known and LAIV was administered owing to a lack of knowledge regarding the recommended use of the vaccine. Interestingly, LAIV vaccination in the second and third trimesters has not decreased in later years as LAIV use has become more widespread, which suggests that some groups of healthcare providers would benefit from increased education regarding the recommended use of LAIV. Hospitalizations or ED visits were uncommon within 42 days of LAIV vaccination. All three hospitalizations that occurred were because of common causes of antepartum hospitalization: hyperemesis gravidarum, threatened premature labor, and pyelonephritis (all at a rate of 0AE7%). Hyperemesis gravidarum has been reported to occur in 0AE3% to 1AE5% of all live births, with most references reporting an incidence of 0AE5%.
14 Threatened premature labor is the most common non-delivery cause of hospitalization among pregnant women, 15 with an incidence rate of firsttime hospitalization of 5AE7% occurring in women from 24 weeks gestational age through delivery. 16 Antepartum hospitalization for pyelonephritis has been reported to occur in 1-2% of all pregnancies. 17, 18 The five ED visits within 42 days post-vaccination were because of common medical conditions, and three of the women had underlying illnesses that may have played contributing roles. The ED visit for bronchitis is notable given that LAIV is a live attenuated virus vaccine. It is not possible to determine whether there was a causal relationship between LAIV and the episode of bronchitis. Acute respiratory infections are common complications of pregnancy, and bronchitis has been found to occur in 1% of all pregnancies. 19 While LAIV can cause minor upper respiratory symptoms such as rhinorrhea or sore throat, clinical studies of LAIV in healthy adults, 20, 21 children and adolescents with asthma, and older adults with chronic obstructive pulmonary disease have not shown an increase in medically attended respiratory events after vaccination. 22, 23 For the women hospitalized for delivery within 42 days of vaccination, the four diagnoses that were potentially new (polyhydramnios, anemia of pregnancy, premature rupture of membranes and transient hypertension) were all common obstetric complications that can be noted for the first time during a hospitalization for delivery. 6, 24 For the five hospitalizations occurring later than 42 days post-vaccination, but before delivery, three were because of common obstetric conditions, 6, 25 one was because of a reoccurrence of pyelonephritis, and one was because of This analysis has several limitations. Despite the very large sample size, the actual number of women in the study who were exposed to LAIV during pregnancy was small. The available sample size was sufficient, with 95% probability, to detect at least one event for outcomes occurring at a frequency of 2AE2% or greater. Additionally, the precision of rate estimates for hospitalization and ED visits because of specific adverse events among these vaccinated women is limited. Consequently, rates of events occurring after vaccination with TIV were not generated for comparison. Furthermore, claims data may not include all diagnoses experienced by a patient, and the codes may lack sufficient specificity for some conditions. Also, because the date of conception was estimated in this study, some misclassification of vaccine exposure by pregnancy status likely occurred. Our study also assumes that there is accurate coding of medical conditions and procedures via specific coding systems. Coding errors could result in classifying another medication or vaccine as LAIV or classifying LAIV as another vaccine. Generally, the rare nature of such errors has minimal impact on quantifying the rate of common events. However, for rare events, such as LAIV vaccination among pregnant women, such errors can erroneously overor underestimate the rate of the event of interest. Coding errors may explain the five subjects who had claims for TIV and LAIV on the same day. Additionally, as noted previously, the 2008-2009 cohort would not include first-trimester vaccinations of women with deliveries after September 2009; however, these vaccinations would have been expected to occur in January through June, months in which LAIV vaccination was rare in the other influenza seasons evaluated. Consequently, the number of 2008-2009 vaccinations that were not captured is expected to be low.
This study is also limited by its lack of claims data regarding birth outcomes. The database we used was unable to link maternal claims data to the claims data describing their offspring. However, existing data from clinical study case reports and spontaneous reports to VAERS have not demonstrated any increased risk of adverse fetal outcomes with LAIV administration during pregnancy. In an analysis of 49 live births whose mothers were vaccinated with LAIV while pregnant, 36 infants were described as 'healthy', 11 had no additional details reported, one infant was delivered prematurely (32-33 weeks gestational age), and one infant was born with clinodactyly, 27 a relatively common hand anomaly charac- terized by curvature of the fifth finger toward the adjacent fourth finger. Also, no vaccine-related fetal malformations or other evidence of teratogenesis were noted in animal developmental toxicity studies. 28 Despite the lack of data regarding outcomes after fetal exposure to LAIV, it is reassuring to note that there is no known fetal injury that has been linked to maternal exposure to wild-type influenza, unlike wild-type viruses for which other live vaccines exist (e.g., varicella and rubella). 29, 30 Finally, we limited evaluated pregnancies to those resulting in the delivery of a child and did not assess spontaneous abortions. Spontaneous abortions may not result in a medical encounter, making the accuracy of the calculations based on claims data unreliable. However, in an analysis of 67 documented LAIV vaccinations during pregnancy from clinical trials and spontaneous VAERS reports, only eight (11AE9%) cases resulted in spontaneous abortions, 27 a proportion that is similar to or below reported national rates of spontaneous abortions and very similar to that reported for TIV in VAERS reports from 1990 to 2009. 8, 31, 32 Despite the aforementioned limitations, this study examined a very large database, which provided a broad reflection of real-world clinical practice within the U.S. The study's unique contribution is the quantification of the frequency of LAIV vaccination during pregnancy and of medically attended adverse event frequencies, which cannot be estimated from spontaneous reporting systems such as VAERS. In this analysis, vaccination with LAIV during pregnancy was uncommon and did not reveal rates of maternal adverse events that differed from those known to occur in the general population of pregnant women. These data may offer some reassurance to providers and pregnant women in the event of inadvertent LAIV administration during pregnancy; however, these data do not support the routine use of LAIV in pregnant women.
